Skip to content

LSD: all studies

Page 26 of 282: studies 251 to 260 of 2,815, newest first. Back to the LSD overview

Research

Characterizing Thalamocortical (Dys)connectivity Following D-Amphetamine, LSD, and MDMA Administration

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging April 29, 2022 Mihai Avram, Felix Müller, Helena Rogg et al. 43 citations

Psychedelics, empathogens, and psychostimulants evoke thalamocortical hyperconnectivity with sensorimotor areas, akin to findings in patients with psychotic disorders.

DOI: 10.1016/j.bpsc.2022.04.003 (opens in new tab) MDMA Amphetamine Hallucinogen Pharmacology

Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders

Frontiers in Psychiatry April 25, 2022 Peter Oehen, Peter Gasser 70 citations

The Swiss Federal Act on Narcotics allows for the restricted medical use of scheduled psychotropic drugs in cases of resistance to standard treatment, and preliminary evidence of efficacy of the scheduled drug for the particular condition. Since 2014, the authors have obtained 50 licenses on a case-by-case basis and developed a psychedelic-assisted group therapy model utilizing MDMA and LSD....

DOI: 10.3389/fpsyt.2022.863552 (opens in new tab) MDMA Psychotherapist Dissociative Clinical psychology

Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex.

Neuroimage April 25, 2022 Manesh Girn, Leor Roseman, Boris C. Bernhardt et al. 112 citations

Lysergic acid diethylamide (LSD) and psilocybin are serotonergic psychedelic compounds with potential in the treatment of mental health disorders. Past neuroimaging investigations have revealed that both compounds can elicit significant changes to whole-brain functional organization and dynamics. A recent proposal linked past findings into a unified model and hypothesized reduced whole-brain...

Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges

Expert Opinion on Drug Safety April 15, 2022 Giordano Novak Rossi, Jaime E. C. Hallak, José Carlos Bouso Saiz et al. 24 citations

There were no serious AEs related to psilocybin and LSD administration. Most AEs were expected, manageable, and transient. Nevertheless, safety and tolerability concerns regarding some effects, such as dissociation, paranoia, and confusion, remain. Thus, randomized controlled trials with bigger samples are warranted to confirm their therapeutic effects and further investigate their safety and...

Cytotoxic, genotoxic, and oxidative stress-related effects of lysergic acid diethylamide (LSD) and phencyclidine (PCP) in the human neuroblastoma SH-SY5Y cell line

Arhiv za Higijenu Rada i Toksikologiju April 1, 2022 Jurič Andreja, Zandona Antonio, Lovaković Blanka Tariba et al. 6 citations

Lysergic acid diethylamide (LSD) is a classic hallucinogen, widely abused for decades, while phencyclidine (PCP) has increased in popularity in recent years, especially among the adolescents. Very little is known about the general toxicity of these compounds, especially about their possible neurotoxic effects at the cell level. The aim of this study was to address these gaps by assessing the...

DOI: 10.2478/aiht-2021-72-3604 (opens in new tab) Full text (opens in new tab) LSD Antioxidant enzymes Cell viability Dna damage +12

Pengalaman Anak Jalanan Usia Remaja Dalam Perilaku Inhalasi Lysergic Acid Diethylamide

Jurnal Ilmu Keperawatan Anak March 30, 2022 Chatarina Suryaningsih, Soleha Hendarsyah 7 citations

Seorang anak bisa menjadi anak jalanan tentu mempunyai hal yang melatarbelakangi dalam kehidupannya. Sehingga anak jalanan sangat rentan untuk terjerumus kedalam perilaku menyimpang salah satunya adalah perilaku inhalasi zat adiktif seperti Lysergic Acid Diethylamide (LSD). Tujuan penelitian ini untuk mengeksplorasi dan menggambarkan pengalaman anak jalanan usia remaja dalam perilaku inhalasi...

A cluster of 25B-NBOH poisonings following exposure to powder sold as lysergic acid diethylamide (LSD)

Clinical Toxicology March 28, 2022 S. Ivory, J. Rotella, Jennifer L. Schumann et al.

Abstract Introduction 25B-NBOH is a synthetic hallucinogen closely related to the “NBOMe” family of N-substituted 2C phenethylamine derivatives. There have been no published reports documenting the clinical toxicity of NBOH derivatives. Case series Five patients presented to the Emergency Department (ED) with altered conscious state following exposure to powder sold as “powdered LSD” at a...

Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD

Psychopharmacology March 24, 2022 Timothy Lawn, Ottavia Dipasquale, Alexandros Vamvakas et al. 48 citations

Abstract Rationale LSD is the prototypical psychedelic. Despite a clear central role of the 5HT 2a receptor in its mechanism of action, the contributions of additional receptors for which it shows affinity and agonist activity remain unclear. Objectives We employed receptor-enriched analysis of functional connectivity by targets (REACT) to explore differences in functional connectivity (FC)...

Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline

Neuropsychopharmacology March 17, 2022 Danilo de Gregorio, Antonio Inserra, Justine P. Enns et al. 89 citations

Lysergic acid diethylamide (LSD) is a serotonergic psychedelic compound receiving increasing interest due to putative anxiolytic and antidepressant properties. However, the potential neurobiological mechanisms mediating these effects remain elusive. Employing in vivo electrophysiology, microionthophoresis, behavioral paradigms and morphology assays, we assessed the impact of acute and chronic...

Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study

Journal of Psychopharmacology March 1, 2022 Peter S. Hendricks, Heith Copes, Neiloufar Family et al. 8 citations

Background: Classic psychedelics show promise in the treatment of mental health conditions; however, more scalable intervention protocols are needed to maximize access to these novel therapeutics. In this proof-of-concept study, perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide (LSD) were evaluated among healthy participants ( N =...

DOI: 10.1177/02698811211055855 (opens in new tab) Lysergic acid diethylamide Thematic analysis Intervention counseling Qualitative research +4